Results 131 to 140 of about 26,315,175 (213)

Copy‐Number Alterations in Central Nervous System Tumours: Diagnostic and Prognostic Implications

open access: yesNeuropathology and Applied Neurobiology, Volume 52, Issue 6, December 2026.
This review summarises recurrent copy‐number alterations across the spectrum of CNS tumours, classifies them into diagnostic, prognostic and supportive categories, and highlights how characteristic CNA combinations support tumour classification, grading and risk stratification in neuropathological diagnostics.
Christian Thomas
wiley   +1 more source

Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS <sup>G12C</sup> NSCLC. [PDF]

open access: yesSci Rep
Giménez-Capitán A   +14 more
europepmc   +1 more source

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2562-2574, 15 November 2026.
While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva   +25 more
wiley   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, Volume 600, Issue 21, Page 3221-3240, November 2026.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2955-2973, November 2026.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2647-2655, November 2026.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2918-2935, November 2026.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy